Advanced Search

Home > Journals > Journal of Neurosurgical Sciences > Past Issues > Journal of Neurosurgical Sciences 2015 March;59(1) > Journal of Neurosurgical Sciences 2015 March;59(1):63-71

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUEJOURNAL OF NEUROSURGICAL SCIENCES

A Journal on Neurosurgery

Indexed/Abstracted in: e-psyche, EMBASE, PubMed/MEDLINE, Neuroscience Citation Index, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,651

Frequency: Quarterly

ISSN 0390-5616

Online ISSN 1827-1855

 

Journal of Neurosurgical Sciences 2015 March;59(1):63-71

    REVIEWS

Indications and therapeutic management of carotid stenosis in high-risk patients: SAPPHIRE and beyond

Munich S. A. 1, 2, Cress M. C. 1, 2, Krishna C. 1, 2, Levy E. I. 1-4

1 Department of Neurosurgery, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA;
2 Department of Neurosurgery, Gates Vascular Institute/Kaleida Health, Buffalo, NY, USA;
3 Department of Radiology, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA;
4 Toshiba Stroke and Vascular Research Center, University at Buffalo, State University of New York, Buffalo, NY, USA

Carotid artery revascularization is an effective means of stroke prevention in selected patients with carotid stenosis. Traditionally, carotid endarterectomy (CEA) was performed to achieve this goal. With the development of endovascular techniques and technologies, carotid artery stenting (CAS) has become a viable alternative to CEA, particularly in patients considered high risk for CEA. The Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy (SAPPHIRE) study single-handedly catapulted CAS to the forefront of therapeutic options for high-risk patients. This study directly compared CAS to CEA in high-risk patients, finding CAS to be equally effective. Since SAPPHIRE, several studies have confirmed the safety and efficacy of CAS in high-risk patients, demonstrating acceptable 1-year morbidity (1-11.3%) and durable target-vessel patency (97.6-98.7%).

language: English


FULL TEXT  REPRINTS

top of page